Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy-Reference-Cited by-同舟云学术

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

Published:2016-03 Issue: Volume:55 Page:7-14
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tokito Takaaki,Azuma Koichi,Kawahara Akihiko,Ishii Hidenobu,Yamada Kazuhiko,Matsuo Norikazu,Kinoshita Takashi,Mizukami Naohisa,Ono Hirofumi,Kage Masayoshi,Hoshino Tomoaki

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Cancer statistics;Siegel;CA Cancer J Clin,2012

2. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer;Blackstock;J Clin Oncol,2007

3. NCCN clinical practice guidelines in oncology: non-small cell lung cancer;National Comprehensive Cancer Network,2014

4. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007;Segawa;J Clin Oncol,2010

5. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105;Yamamoto;J Clin Oncol,2010

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of ferroptosis-related lncRNAs for predicting prognosis and immunotherapy response in non-small cell lung cancer;Future Generation Computer Systems;2024-10

2. Predicting Durable Clinical Benefits of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer: A Nomogram Based on CT Imaging and Immune Type;Academic Radiology;2024-08

3. Pan-cell death-related signature reveals tumor immune microenvironment and optimizes personalized therapy alternations in lung adenocarcinoma;Scientific Reports;2024-07-08

4. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy;Biomedicines;2024-03-19

5. Blood Lymphocytes as a Prognostic Factor for Stage III Non-Small Cell Lung Cancer with Concurrent Chemoradiation;Chonnam Medical Journal;2024